As European markets navigate the challenges of new U.S. trade tariffs and fluctuating economic indicators, the pan-European STOXX Europe 600 Index recently experienced a decline of about 1.4%, reflecting broader market sentiment impacted by geopolitical tensions and inflation concerns. In this environment, identifying high-growth tech stocks requires a focus on companies with strong fundamentals and innovative capabilities that can adapt to shifting market dynamics while maintaining robust growth potential.
Top 10 High Growth Tech Companies In Europe
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Pharma Mar | 24.24% | 40.82% | ★★★★★★ |
Archos | 24.45% | 65.92% | ★★★★★★ |
Yubico | 20.88% | 26.53% | ★★★★★★ |
Truecaller | 20.10% | 24.70% | ★★★★★★ |
Elicera Therapeutics | 63.53% | 97.24% | ★★★★★★ |
XTPL | 97.45% | 117.95% | ★★★★★★ |
Devyser Diagnostics | 26.38% | 95.42% | ★★★★★★ |
Ascelia Pharma | 46.09% | 66.93% | ★★★★★★ |
CD Projekt | 33.68% | 36.76% | ★★★★★★ |
Elliptic Laboratories | 49.76% | 88.21% | ★★★★★★ |
Let's uncover some gems from our specialized screener.
argenx (ENXTBR:ARGX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: argenx SE is a commercial-stage biopharmaceutical company that focuses on developing therapies for autoimmune diseases across multiple regions, including the United States, Japan, China, and the Netherlands, with a market capitalization of €33.15 billion.
Operations: argenx SE generates revenue primarily from its biotechnology segment, which amounts to $2.25 billion. The company focuses on developing therapies for autoimmune diseases across multiple regions, including the United States, Japan, China, and the Netherlands.
Argenx SE has demonstrated a robust turnaround, reporting a significant revenue increase to $2.25 billion in 2024 from $1.27 billion the previous year, alongside transitioning from a net loss of $295 million to a net income of $833 million. This financial rebound is underscored by an impressive annual earnings growth forecast at 28.3%. The company's commitment to innovation is evident in its recent clinical trial announcements, which could enhance its competitive edge within the biotech sector. These developments not only reflect Argenx's strategic agility but also position it well for sustained growth, leveraging advanced therapies that meet critical healthcare needs.
- Navigate through the intricacies of argenx with our comprehensive health report here.
Examine argenx's past performance report to understand how it has performed in the past.
CD Projekt (WSE:CDR)
Simply Wall St Growth Rating: ★★★★★★
Overview: CD Projekt S.A., along with its subsidiaries, focuses on developing, publishing, and digitally distributing video games for PCs and consoles in Poland, with a market capitalization of PLN20.98 billion.
Operations: The company generates revenue primarily through its CD PROJEKT RED segment, contributing PLN801.64 million, and GOG.Com segment with PLN199.34 million. The net profit margin trend is a key focus for analysis when evaluating financial performance.
CD Projekt, navigating a challenging year with a revenue dip to PLN 985.03 million from PLN 1,230.2 million, still managed to maintain robust net income at PLN 469.87 million. Despite slight decreases in EPS, the company's focus on strategic growth is evident with expected annual revenue and earnings growth at impressive rates of 33.7% and 36.8%, respectively—substantially outpacing the Polish market averages of 4.4% and 12.7%. These figures underscore CD Projekt's resilience and innovation in software development, positioning it favorably for future advancements in the gaming industry.
- Click here and access our complete health analysis report to understand the dynamics of CD Projekt.
Understand CD Projekt's track record by examining our Past report.
Nagarro (XTRA:NA9)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Nagarro SE, along with its subsidiaries, offers digital product engineering and technology solutions across North America, Central Europe, the rest of Europe, and internationally, with a market cap of €988.65 million.
Operations: Nagarro generates revenue primarily from its computer services segment, amounting to €947.15 million. The company operates internationally, providing digital product engineering and technology solutions.
Nagarro SE, amidst a flurry of industry presentations and leadership changes, continues to demonstrate robust growth dynamics in the high-tech European market. With an anticipated revenue increase to between €1.02 billion and €1.08 billion for 2025, the company outpaces Germany's average growth rate, reflecting its strategic agility in adapting to tech trends. Further bolstering its competitive edge, Nagarro has committed significant resources towards R&D, ensuring continuous innovation and enhancement of its software solutions portfolio. This investment in future technologies is crucial as it navigates a highly competitive landscape marked by rapid technological advancements and shifting market demands.
- Get an in-depth perspective on Nagarro's performance by reading our health report here.
Gain insights into Nagarro's past trends and performance with our Past report.
Make It Happen
- Click through to start exploring the rest of the 235 European High Growth Tech and AI Stocks now.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Nagarro might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About XTRA:NA9
Nagarro
Provides digital product engineering and technology solutions in North America, Central Europe, rest of Europe, and internationally.
Undervalued with excellent balance sheet.
Market Insights
Community Narratives

